Revelation Biosciences (NASDAQ:REVB) Announces Earnings Results

Revelation Biosciences (NASDAQ:REVB) issued its quarterly earnings results on Thursday. The company reported ($2.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($1.56), FiscalAI reports.

Revelation Biosciences Stock Performance

Revelation Biosciences stock traded down $0.06 during trading hours on Friday, reaching $0.96. 224,262 shares of the company’s stock traded hands, compared to its average volume of 76,426. The firm has a market capitalization of $3.57 million, a price-to-earnings ratio of -0.02 and a beta of -0.14. Revelation Biosciences has a fifty-two week low of $0.95 and a fifty-two week high of $40.08. The firm’s 50 day moving average is $1.20 and its 200-day moving average is $2.60.

Institutional Investors Weigh In On Revelation Biosciences

A hedge fund recently raised its stake in Revelation Biosciences stock. Armistice Capital LLC raised its holdings in Revelation Biosciences, Inc. (NASDAQ:REVB) by 442.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 434,272 shares of the company’s stock after acquiring an additional 354,272 shares during the quarter. Armistice Capital LLC owned about 6.29% of Revelation Biosciences worth $347,000 as of its most recent SEC filing. 12.80% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, April 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.